Hawthorn: Pharmacology and therapeutic uses

American Journal of Health-System Pharmacy

Volumn 59, Issue 5, 2002, Pages 417-422

  Rigelsky, Janene M ^a   Sweet, Burgunda V ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Alternative medicine; Cardiovascular diseases; Clinical studies; Crataegus oxyacantha; Dosage; Drug administration; Drug interactions; Heart failure; Plants; Toxicity

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; CRATAEGUS EXTRACT; FLAVONOID; VASODILATOR AGENT;

AGITATION; ALTERNATIVE MEDICINE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BLOOD FLOW; CRATAEGUS OXYACANTHA; DIAPHORESIS; DRUG INHIBITION; DRUG POTENTIATION; DYSPNEA; EXERCISE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART PALPITATION; HUMAN; HYPERCHOLESTEROLEMIA; INOTROPISM; MEDICINAL PLANT; NEPHROLITHIASIS; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; VERTIGO;

EID: 0036500303     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.5.417     Document Type: Review

References (37)

1. Hawthorn (shan zha) drink and its lowering effect on blood lipid levels in humans and rats
2. Hawthorn
3. Hawthorn: A literature review
4. Crataegus species
5. Hawthorn
6. Botanical influences on cardiovascular disease
7. Plants with hypotensive, anti-atheromatous and coronarodilatating action
8. Herbal medicine for the treatment of cardiovascular disease
9. Hypolipidemic activity of tincture of Crataegus in rats
10. Myocardial effects of flavonoids from Crataegus species
11. Phytochemicals and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
12. Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes
13. Comparative studies on the effects of a Crataegus extract, digitoxin, digoxin, and g-strophanthin in the isolated heart of homeothermals
14. Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet
15. Pharmacologic profile of Crataegus extract compared to epinephrine, amrinone, milrinone, and digoxin in isolated guinea pig hearts
16. Crataegus-extrakt hilft dem patienten mit NYHA II-herzinsuffizienz
17. High-dose Crataegus (hawthorn) extract WS 1442 for the treatment of NYHA class II heart failure patients
18. Treatment of decreasing cardiac performance in advanced age with standardized Crataegus extract
19. Effectiveness of hawthorn extract at a dosage of 3 × 100 mg per day. Multicentre double-blind trial with 85 NYHA stage II heart failure patients
20. Efficacy of the hawthorn extract LI 132 (600 mg/d) during eight weeks' treatment. Placebo-controlled double-blind trial with 78 NYHA stage II heart failure patients
21. Crataegus for moderately reduced left ventricular ejection fraction. Ergospirometric monitoring study with 72 patients in a double-blind comparison with placebo
22. Objective confirmation of the efficacy of Crataegus-specialextrakt (a special Crataegus extract) WS 1442 in patients with cardiac insufficiency (NYHA II)
23. Effectiveness of the hawthorn extract LI 132 compared with the ACE inhibitor captopril. Multicenter double-blind study with 132 NYHA stage II heart failure patients
24. Clinical effect of Crataegutt in ischemic heart disease and/or hypertensive origin
25. Hawthorn/passion flower extract and improvement in physical exercise capacity of patients with dyspnea class II of the NYHA functional classification
26. Crataegus special extract WS 1442 in NYHA II heart failure: A placebo controlled randomized double-blind study
27. Use of hawthorn extract (Crataegus) for the management of CHF
28. Crataegus
29. Preparation and pharmacological investigation of a new therapeutic agent obtained from Crataegus oxyacantha